http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SU-1705303-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f48e70212a912f2845491b7ff332b506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49e6d8f504fee44e8bb05bafe0e8eab3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14 |
| filingDate | 1987-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1992-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64c15deec7e4747d1b8ba2a2e080b4ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9251fc96845b50307992471726bf36a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a462891f14c7fae0875fffabd4d3229a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13459d626ef88f1b0bf46a004438bd8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2334329fffb9e137a0ef40b621bd998 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ada0f20b9cf4fe3c7456826683f583f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a71c851893fe439d87ffcfb8e0686e54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19ed004ac8d61304877a3098db6b89f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a756d87f083299c5daa52853d0543b33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8498327641f9dbe181ba6c9d64276fc4 |
| publicationDate | 1992-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | SU-1705303-A1 |
| titleOfInvention | Method of glycopeptides synthesis |
| abstract | The invention relates to glycopeptides. in particular, the preparation of compounds of common phla: CH, OH «v. BUT NHAc UNHAc CHjCH-SUSH The invention relates to the synthesis of glycopeptides that can be used in medicine, immunology and veterinary medicine as immunomodulators. The purpose of the invention is to increase the yield and simplify the process. The drawing shows a diagram explaining the method. Example 1. Preparation of M-acetyl-glucosaminyl-1-4) -m-acetylmuramyl - (/ 9 1-4) -M-acetylglucosaminyl- (ft where l is 1 or 2; NHR is the residue of an amino acid or peptide of f-ly L-Ala-Dei-Glu; L-Ala-Del-Gln or L-Ala, used in immunology and veterinary medicine as immunomodulators. The goal is to increase the yield of the target product and simplify the process. It is carried out by N-acetyl sugar (or its salts with an organic base) with a protected amino acid or peptide in the presence of a condensing agent - acpentafluorophenyl carbonate or di (4-chloro-2,3.5,6-tetrachlorophenyl) carbonate with and molar ratio (M, 3) :( 1-1.2): 1 at 0-20 ° C, followed by cleavage of the protective groups and chromatographic purification of the target product. Condensation is carried out in the presence of a base in a solvent (cimethylformamide). These conditions allow They use more accessible substances, provide a better ecology of the process, increase the yield of the target product by 10–25%, reduce the duration of the process from 28 to 5–10 hours, and reduce the number of chromatographic purifications. 1 tab., 1 Il. 1-4) -m-acetylmuramyl-1-alanyl-0-iso-glutamic acid (IV). 9.74 g (10 mM) of tetrasaccharide II. () was dissolved in 25.0 ml of distilled dimethylformamide, 4 ml of M-methylmorpholine was added, stirred for 10-15 minutes, and the solution was poured into 200 ml of ethyl acetate. The precipitate formed is filtered off, washed with 4x50 ml of ethyl acetate, 2x50 ml of hexane, dried and yielded 11.65 g (99%) of M-methyl morpholine salt of tetrasaccharide (V). h | About SP W about SA |
| priorityDate | 1987-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.